Company Research Report: AMR Action Fund
Company Overview
- Name: AMR Action Fund
- Mission: The AMR Action Fund aims to enable breakthroughs in antimicrobials by investing in companies that develop urgently needed therapeutics for priority pathogens. It advocates for market reforms to change how society values these lifesaving drugs. Their aim is to help launch two to four new antimicrobials within the next decade and create a sustainable ecosystem for investment and innovation.
- Founded: The concept originated in discussions among the International Federation of Pharmaceutical Manufacturers and Associations, the World Health Organization (WHO), the European Investment Bank, and the Wellcome Trust. Specific founding year is not provided.
- Key People:
- Henry Skinner, PhD, MBE, MJur - Chief Executive Officer
- Martin Heidecker, PhD, MBA - Chief Investment Officer
- Bill Burns - Board Chair
- David Hellmuth, JD - General Counsel and Chief Operating Officer
- John Vancura, MBA - Chief Financial Officer
- Additional team members, including venture analysts and policy directors
- Headquarters: No information is available
- Number of Employees: No information is available
- Revenue: No information is available
- Known For: The AMR Action Fund is the world’s largest venture capital fund dedicated to investing in antimicrobial therapeutics.
Products
- Overview: The AMR Action Fund does not produce consumer products but makes equity investments in biotechnology companies.
- Key Products: No direct consumer products, but focuses investments on antimicrobial therapeutics.
- Key Features:
- Investments are directed towards clinical-stage companies working on traditional small-molecule compounds and innovative modalities such as bacteriophages and antibody treatments.
- Prioritizes companies dealing with WHO and CDC priority pathogens.
Recent Developments
- Recent Developments:
- The AMR Action Fund continues to build a global network of syndicate financial partners and leads or co-leads investments each year into promising antimicrobial companies.
- New Products Launched: No information on specific products launched. However, their goal is to help bring 2 to 4 new antibiotics to market by the end of the decade.
- New Features Added: No information is available on new features.
- New Partnerships:
- Expanded its portfolio with an investment in TenNor Therapeutics as of October 16, 2024.
Additional Information
- Threat of AMR: Antimicrobial-resistant bacteria kill nearly 1.3 million people annually, more than HIV/AIDS or malaria. The Fund exists in response to this escalating global health challenge.
- Investments: Focused on creating a sustainable ecosystem of innovation and investment in the field of antimicrobials.
- News Highlights:
- Numerous media features and discussions related to antimicrobial resistance and the global health implications.
Note: This report is based solely on the available data and outlines significant aspects of the AMR Action Fund. No additional commentary or analysis is included beyond the provided information.
